Navigation Links
Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Date:11/23/2009

PRINCETON, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The decision was reached after a scheduled review by an independent Data Monitoring Committee (DMC) of all available safety data from the first cohort of approximately 100 patients completing 8 or 12 weeks of RG7128 or matching placebo in combination with pegylated interferon and ribavirin.

The DMC reviewed any potential drug discontinuations, incidence and details of adverse events, and selected laboratory assessments. No safety events in the DMC review were considered significantly different from those expected from HCV patients taking pegylated interferon and ribavirin treatment. The committee expressed no safety concerns that would preclude enrollment of the remaining 300 patients in the ongoing phase 2b study in the HCV positive genotype 1 and 4 population, and have not recommended modification of dose or duration of any RG7128 dosing regimens. Enrollment of these patients pre-screened for this Cohort in the fourth quarter 2009 has begun and is expected to be complete by the end of the first quarter of 2010.

"We welcome Roche's decision to open enrollment of Cohort 2 for the remaining 300 patients in the phase 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "We are encouraged by the safety profile of RG7128 to date, which, when coupled with the higher barrier to resistance offered by nucleoside and nucleotide analog inhibitors has the potential to improve SVR rates over the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... that widens the obstructed blood vessels. This report ... and future prospects of the market. The report ... market snapshot that provides overall information of various ... section also provides the overall information and data ...
(Date:9/2/2015)... 2, 2015 About implantable medical devices ... to replace, augment, or repair damaged tissues or ... of applications including cosmetic, spinal, cardiovascular, ophthalmic, and ... different materials such as polymers, metals, ceramics, and ... medical devices market to grow at a CAGR ...
(Date:9/2/2015)...  The report on breast cancer therapeutics: pipeline analysis ... on the basis of the molecules which are currently ... lining of milk ducts or lobules responsible for supplying ... that can spread to other cells present in the ... is referred as lobular carcinoma, while the other that ...
Breaking Medicine Technology:Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Implantable Medical Devices Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
... Corporation (Nasdaq: SIAL ) will be presenting at ... 1:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High ...
... 23, 2011 ViewRay™, Inc., a privately held ... clearance for its radiotherapy treatment planning and delivery ... the company,s new radiation therapy system, which combines ... in the late stages of development, the integrated ...
Cached Medicine Technology:ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software 2
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
(Date:9/3/2015)... ... 2015 , ... Leading post-acute electronic medical record (EMR) software ... the company’s executive leadership team as VP of Product and as VP of ... product and project management. He has been with HealthWyse since 2000 in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... and efficient customer and technical support services to promote LodonalTM in Nigeria. The ... trial evaluating the efficacy and safety of the product. , Managing Director, Fidson ...
(Date:9/2/2015)... , ... September 03, 2015 , ... The Aspen ... services - two retreats geared towards kick-starting and inspiring wellness in the Roaring Fork ... a part of developing a whole mind-body approach to fitness - we are much ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2
... women receiving the same breast cancer treatments as Hispanic ... lower survival rates, were more likely to be diagnosed// ... to a study. ,For the study, ... M. D. Anderson Cancer Center and colleagues examined 2,140 ...
... According to a recent analysis by Metropolitan Transportation Authority, ... excessive dieting are among the top// causes, after the ... US subway. ,Asim Nelson, a transit ... statistics, taken between October 2005 and October 2006, shows ...
... among states and union territories to enforce screening of all ... disorder// that could lead to disabilities. ,Chandigarh ... children would be done to check any adverse fallout later. ... ,While poor people would be provided the facility ...
... giant-Coco Cola and Nestle have come together to manufacture a ... tea, caffeine and plant micronutrients. This is expected to hit ... consumers shed excess weight. ,According the chief scientist ... calories burnt. The soft drink company claims that detailed studies ...
... proposal released by Gov. Arnold Schwarzenegger recently, workers in ... benefit - to their// health and wealth. Employees will ... exempted from tax. ,The proposal is an ... reachable to the approximate 6.5 million Californians who are ...
... make you diabetic, says a study that tracked hospitalisation rates ... ,Type-two diabetes has seen a two-fold increase - from ... While scientists scramble to find explanations for the rise, experts ... , ,However, the study by Lawrence Lessner and colleagues ...
Cached Medicine News:Health News:Living Near Toxic Waste May Bring On Diabetes 2